BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ACell, Inc. Announces Completion Of $6.0 Million Financing Round


10/19/2005 5:10:31 PM

JESSUP, Md., March 22 /PRNewswire/ -- ACell, Inc. announced that it has completed a $6.0 million financing. Capital raised in this first round of financing will be used for general corporate purposes, including strengthening ACell's position as the leader in regenerative medicine-based veterinary products and developing the Company's portfolio of medical products.

Jim DeFrancesco, ACell's CEO, stated: "We are pleased to have completed our first round of financing, and are encouraged by the tremendous interest shown in ACell and our proprietary technology. This financing will enable ACell to expand our base of veterinary customers while we move ACell's regenerative medicine-based products forward in the medical field."

ACell, Inc. was incorporated in Delaware in June 1999 for the purpose of developing, manufacturing, and marketing products in the field of regenerative medicine. These tissue engineered products are based on naturally occurring, extracellular matrix (ECM) scaffolds. The Company's proprietary ECM technology changes the fundamental healing response by encouraging the body's own regenerative capabilities to repair tissues and restore them to natural health. ACell currently markets veterinary products that promote the restoration of tissue in acute and chronic skin wounds, surgery, corneal ulcers, and tendon and ligament injuries.

ACell, Inc.

CONTACT: Miles Grody of ACell, Inc., +1-301-983-6830, ormilesgrody@acell.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES